Menu

BNP-45 (Rat) - EIA Kit

Quantity:

Catalog #
Size
Price
EK-011-17 96 wells $465

  • Protocol:
  • View/Download (PDF) - for reference only
  • Sample Preparation:
  • Suggested Procedure
  • Sample Extraction:
  • Recommended
  • Sensitivity: polaroid
    Data may differ slightly based on lot.
  • 0.3 ng/ml
  • Linear Range: polaroid
    Data may differ slightly based on lot.
  • 0.3 - 4.73 ng/ml
  • Cross Reactivity:
  • Peptide

    %

    BNP-45 (Rat)

    100

    BNP-32(Rat)

    100

    BNP-45 (Mouse)

    11.3

    BNP-32 (Porcine)

    0

    BNP-26 (Porcine)

    0

    BNP-32 (Human)

    0

    BNP-32 (Canine)

    0

    ANP (Rat)

    0

    a-ANP (1-28) (Human, Canine)

    0

    Endothelin-1

    0

    Angiotensin II (Human)

    0


  • Intra-assay variation:
  • <10%
  • Inter-assay variation:
  • <15%
  • MSDS:
  • View/Download
Standard Curve:

PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.
Deres L, Bartha E, Palfi A, et al. PLoS ONE. 2014;9(7):e102148.

Increased cardiovascular risk in rats with primary renal dysfunction; mediating role for vascular endothelial function.
Szymanski MK, Buikema JH, Van veldhuisen DJ, et al. Basic Res Cardiol. 2012;107(2):242.

Stem-cell therapy in an experimental model of pulmonary hypertension and right heart failure: role of paracrine and neurohormonal milieu in the remodeling process.
Angelini A, Castellani C, Ravara B, et al. J Heart Lung Transplant. 2011;30(11):1281-93.

Characterization of cardiac size and function in SHRSP.Z-Lepr(fa)/IzmDmcr rats, a new animal model of metabolic syndrome.
Tada Y, Kagota S, Matsumoto M, et al. Biol Pharm Bull. 2010;33(12):1971-6.

Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
Van esch JH, Moltzer E, Van veghel R, et al. J Hypertens. 2010;28(10):2145-55.

Gene expression of ANP, BNP and ET-1 in the heart of rats during pulmonary embolism.
Gutte H, Oxbøl J, Kristoffersen US, Mortensen J, Kjaer A. PLoS ONE. 2010;5(6):e11111.

PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
Bartha E, Solti I, Kereskai L, et al. J. Cardiovasc Res. 2009;83(3):501-10.

Expression of B-type natriuretic peptide-45 (BNP-45) gene in the ventricular myocardial induced by systemic chronic hypoxia.
Ferdinal F, Suyatna FD, Wanandi SI, Sadikin M. Acta Med Indones. 2009;41(3):136-43.

Bartha et al. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
J Cardiovasc Pharmacol. 2008 Sep;52(3):253-61.

PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Palfi et al. J Mol Cell Cardiol. 2006 Jul;41(1):149-59.

Cardioprotective effects of poly(ADP-ribose) polymerase inhibition.
Szabó C. Pharmacol Res. 2005;52(1):34-43.